DC-ATA Uses, Dosage, Side Effects and more
DC-ATA is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.
| Trade Name | DC-ATA |
| Generic | AV-COVID-19 |
| AV-COVID-19 Other Names | DC-ATA, DCV |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
